Dominant doubly charged ion enabling robust LC–MS/MS quantification of a novel small-molecule antibacterial drug Cefidelbaz in human plasma and its application to pharmacokinetic and protein binding studies
Journal of Pharmaceutical and Biomedical Analysis · 2027
DOI: 10.1016/j.jpba.2026.117725 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical and Biomedical Analysis, 2027. Verfasst von Chenxin Ding und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China; Nanjing Clinical Tech. Laboratories Inc., Nanjing, China. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Anti-Bacterial Agents, Cephalosporins, Liquid Chromatography-Mass Spectrometry. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
Cefidelbaz is a novel siderophore cephalosporin antibacterial agent with a unique "Trojan horse" mechanism, which can combat some of the most difficult-to-treat Gram-negative bacterial infections. In mass spectrometric analysis, cefidelbaz generated distinct precursor ions in both positive and negative modes during the first-quadrupole full-scan (Q1 full-scan), while multiple precursor ions with different charge states were observed in positive mode. Notably, singly charged precursor ions in either positive or negative mode failed to provide wide linear range and high sensitivity, whereas the doubly charged precursor ions enabled reliable and reproducible quantitative analysis. These findings, together with reported charge-state behavior of cephalosporins with zwitterionic character, demonstrated that the optimal precursor ions should be selected according to experimental quantitative performance. Here, two independent LC-MS/MS (liquid chromatography-tandem mass spectrometry) methods were developed. The first method was established for the quantification of total cefidelbaz in human plasma, with a calibration range of 1.00-600 µg/mL. The second method, based on ultrafiltration coupled with LC-MS/MS, was developed for the determination of plasma protein binding (%PPB), covering a calibration range of 0.500-250 µg/mL. Overall, this study demonstrated the importance of precursor ions selection for reliable LC-MS/MS quantification of cephalosporins with zwitterionic character and provides validated bioanalytical methods to support clinical development of cefidelbaz.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China; Nanjing Clinical Tech. Laboratories Inc., Nanjing, China.
- Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.
- Nanjing Jiening Pharmaceutical Technology Co., Ltd., Nanjing, China.
- Nanjing Clinical Tech. Laboratories Inc., Nanjing, China.
- Nanjing Clinical Tech. Laboratories Inc., Nanjing, China. Electronic address: xiaoyatopone@163.com.
- Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China; Nanjing Clinical Tech. Laboratories Inc., Nanjing, China. Electronic address: dingli@cpu.edu.cn.
Zitieren
APA
Ding, C., Li, X., Wu, Y., Wang, J., Wang, S., Wang, Y., & Ding, L. (2027). Dominant doubly charged ion enabling robust LC–MS/MS quantification of a novel small-molecule antibacterial drug Cefidelbaz in human plasma and its application to pharmacokinetic and protein binding studies. Journal of Pharmaceutical and Biomedical Analysis. https://doi.org/10.1016/j.jpba.2026.117725
Vancouver
Ding C, Li X, Wu Y, Wang J, Wang S, Wang Y, et al. Dominant doubly charged ion enabling robust LC–MS/MS quantification of a novel small-molecule antibacterial drug Cefidelbaz in human plasma and its application to pharmacokinetic and protein binding studies. Journal of Pharmaceutical and Biomedical Analysis. 2027. doi:10.1016/j.jpba.2026.117725
BibTeX
@article{Ding2027,
author = {Ding, Chenxin and Li, Xiuyang and Wu, Yijue and Wang, Jun and Wang, Shuai and Wang, Yiya and Ding, Li},
title = {Dominant doubly charged ion enabling robust LC–MS/MS quantification of a novel small-molecule antibacterial drug Cefidelbaz in human plasma and its application to pharmacokinetic and protein binding studies},
journal = {Journal of Pharmaceutical and Biomedical Analysis},
year = {2027},
doi = {10.1016/j.jpba.2026.117725}
}
EUVIMED